Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 8/20 | 0.59 |
| ▸ | MMP12 | P39900 | 5/20 | 0.59 |
| ▸ | MMP13 | P45452 | 3/20 | 0.59 |
| ▸ | MMP2 | P08253 | 5/20 | 0.52 |
| ▸ | MMP3 | P08254 | 3/20 | 0.52 |
| ▸ | MMP7 | P09237 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251185 | 0.86 | ADAM17 (0.62) | ADAM17MMP12MMP13MMP2MMP3 | |
| SCHEMBL5252129 | 0.84 | ADAM17 (0.61) | ADAM17MMP12MMP13MMP2MMP3 | |
| SCHEMBL5249328 | 0.83 | ADAM17 (0.59) | ADAM17MMP12MMP13MMP2MMP3 | |
| SCHEMBL5866619 | 0.80 | ADAM17 (0.71) | ADAM17MMP3MMP7 | |
| SCHEMBL5255328 | 0.78 | MMP3 (0.81) | ADAM17MMP12MMP13MMP2MMP3 | |
| SCHEMBL5250124 | 0.78 | MMP2 (0.61) | ADAM17MMP12MMP13MMP2MMP3 | |
| SCHEMBL5253094 | 0.77 | ADAM17 (0.73) | ADAM17MMP12MMP13MMP2MMP3 | |
| SCHEMBL5250139 | 0.77 | ADAM17 (0.54) | ADAM17MMP12MMP13MMP2MMP3 | |
| Trifluoroacetic Acid SCHEMBL5866692 | 0.76 | MMP3 (0.74) | ADAM17MMP12MMP13MMP2MMP3 | |
| SCHEMBL5866634 | 0.76 | ADAM17 (0.67) | ADAM17MMP12MMP13MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558581-A4 | TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-07-25 | — | — | EP | claimed |
| US-7074810-B2 | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-11 | — | — | US | claimed |
| EP-1558581-A2 | TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-08-03 | — | — | EP | claimed |
| US-20040116491-A1 | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-17 | — | — | US | claimed |
| WO-2004032846-A2 | TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | claimed |
| EP-1558581-A4 | TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7074810-B2 | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1558581-A2 | TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040116491-A1 | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-17 | — | — | US | disclosed |
| WO-2004032846-A2 | TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | disclosed |